Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib.
Soverini S, Gnani A, De Benedittis C, Castagnetti F, Gugliotta G, Iacobucci I, Palandri F, Rosti G, Testoni N, Luatti S, Marzocchi G, Baccarani M, Martinelli G. Soverini S, et al. Among authors: de benedittis c. Leuk Res. 2011 Nov;35(11):1527-9. doi: 10.1016/j.leukres.2011.05.029. Epub 2011 Jul 16. Leuk Res. 2011. PMID: 21762985
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain.
Soverini S, De Benedittis C, Machova Polakova K, Brouckova A, Horner D, Iacono M, Castagnetti F, Gugliotta G, Palandri F, Papayannidis C, Iacobucci I, Venturi C, Bochicchio MT, Klamova H, Cattina F, Russo D, Bresciani P, Binotto G, Giannini B, Kohlmann A, Haferlach T, Roller A, Rosti G, Cavo M, Baccarani M, Martinelli G. Soverini S, et al. Among authors: de benedittis c. Blood. 2013 Aug 29;122(9):1634-48. doi: 10.1182/blood-2013-03-487728. Epub 2013 Jun 21. Blood. 2013. PMID: 23794064 Free article.
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.
Soverini S, De Benedittis C, Polakova KM, Linhartova J, Castagnetti F, Gugliotta G, Papayannidis C, Mancini M, Klamova H, Salvucci M, Crugnola M, Iurlo A, Albano F, Russo D, Rosti G, Cavo M, Baccarani M, Martinelli G. Soverini S, et al. Among authors: de benedittis c. Oncotarget. 2016 Apr 19;7(16):21982-90. doi: 10.18632/oncotarget.8010. Oncotarget. 2016. PMID: 26980736 Free PMC article.
Best Practices in Chronic Myeloid Leukemia Monitoring and Management.
Soverini S, De Benedittis C, Mancini M, Martinelli G. Soverini S, et al. Among authors: de benedittis c. Oncologist. 2016 May;21(5):626-33. doi: 10.1634/theoncologist.2015-0337. Epub 2016 Mar 31. Oncologist. 2016. PMID: 27032870 Free PMC article. Review.
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
Soverini S, De Benedittis C, Castagnetti F, Gugliotta G, Mancini M, Bavaro L, Machova Polakova K, Linhartova J, Iurlo A, Russo D, Pane F, Saglio G, Rosti G, Cavo M, Baccarani M, Martinelli G. Soverini S, et al. Among authors: de benedittis c. BMC Cancer. 2016 Aug 2;16:572. doi: 10.1186/s12885-016-2635-0. BMC Cancer. 2016. PMID: 27485109 Free PMC article.
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage.
Mancini M, Castagnetti F, Soverini S, Leo E, De Benedittis C, Gugliotta G, Rosti G, Bavaro L, De Santis S, Monaldi C, Martelli M, Santucci MA, Cavo M, Martinelli G. Mancini M, et al. Among authors: de benedittis c, de santis s. J Cell Biochem. 2017 Nov;118(11):3968-3975. doi: 10.1002/jcb.26052. Epub 2017 May 30. J Cell Biochem. 2017. PMID: 28401599
47 results